NEW YORK (GenomeWeb) – OneOme announced today that it has partnered with Total Quality Medicine (TQM) to offer its pharmacogenomic testing and support services in Mexico.
Under the terms of the deal, OneOme's PCR-based RightMed genetic test — which covers 22 genes in which variants are known to contribute to the effectiveness or safety of more than 340 drugs for more than 20 indications — will be incorporated into Mexico City-based TQM's GeneTest line of personalized medicine products.
Additional terms of the deal were not disclosed.
"OneOme's pharmacogenomic testing will complement the great advances TQM is making to improve precision medicine in Mexico," OneOme CEO Paul Owen said in a statement. "Launching this partnership means that medical providers and patients will be able to access OneOme's product to personalize medicine and improve health."
OneOme began as a joint venture between the Mayo Clinic and early-stage venture firm Invenshure, and launched RightMed last year. Earlier this month, the company formed an alliance with Genome.One to offer the test in Australia.